SCHEMBL2123175

SCHEMBL2123175

CS(=O)(=O)Nc1ccccc1Nc1nc(Nc2cnn(CC(F)F)c2)ncc1F

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 4/20 0.63
PTK2 Q05397 2/20 0.50
GSK3A P49840 1/20 0.48
LRRK2 Q5S007 1/20 0.48
MAPK15 Q8TD08 1/20 0.48
CAMKK2 Q96RR4 1/20 0.48
JAK2 O60674 4/20 0.44
JAK1 P23458 4/20 0.44
JAK3 P52333 4/20 0.44
ALK Q9UM73 3/20 0.44
AURKA O14965 5/20 0.44
AURKB Q96GD4 1/20 0.44
MET P08581 1/20 0.44
CDC7 O00311 1/20 0.44
MAPK8 P45983 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124772 0.91 GLO1 (0.56) GLO1PTK2GSK3AJAK2JAK1
SCHEMBL2123044 0.86 GLO1 (0.58) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL2121008 0.85 GLO1 (0.69) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL2124022 0.84 GLO1 (0.57) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL2122067 0.82 GLO1 (0.55) GLO1GSK3ALRRK2MAPK15CAMKK2
SCHEMBL1039144 0.81 GLO1 (0.83) GLO1PTK2GSK3ALRRK2MAPK15
SCHEMBL656107 0.81 GLO1 (0.78) GLO1PTK2GSK3ALRRK2MAPK15
SCHEMBL1039614 0.80 GLO1 (0.83) GLO1PTK2GSK3ALRRK2MAPK15
SCHEMBL12795375 0.79 PTK2 (0.44) GLO1PTK2JAK2JAK1JAK3
SCHEMBL16812381 0.79 JAK3 (0.63) PTK2JAK2JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US claimed
EP-2443106-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS Cellzome Limited (GB) 2012-04-25 EP claimed
WO-2010146133-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 WO claimed
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2012-07-05 US disclosed
EP-2443106-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS Cellzome Limited (GB) 2012-04-25 EP disclosed
WO-2010146133-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172384-A1 HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS ZAP70, JAK3, JAK2 GLO1 3371/4885PTK2 168/4885GSK3A 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.